Literature DB >> 6256765

Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.

D A Carson, D B Wasson, J Kaye, B Ullman, D W Martin, R K Robins, J A Montgomery.   

Abstract

An inherited deficiency of adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) produces selective lymphopenia and immunodeficiency disease in humans. Previous experiments have suggested that lymphospecific toxicity in this condition might result from the selective accumulation of toxic deoxyadenosine nucleotides by lymphocytes with high deoxycytidine kinase, levels and low deoxynucleotide dephosphorylating activity. The present experiments were designed to determine if deoxyadenosine analogs which are not substrates for adenosine deaminase might similarly be toxic toward lymphocytes and lymphoid tumors. Two such compounds, 2-chlorodeoxyadenosine and 2-fluorodeoxyadenosine, at concentrations of 3 nM and 0.15 microM, respectively, inhibited by 50% the growth of human CCRF-CEM malignant lymphoblasts in vitro. Each was phosphorylated in intact cells by deoxycytidine kinase accumulated as the nucleoside triphosphate, and inhibited DNA synthesis more than RNA synthesis. Both deoxynucleosides had significant chemotherapeutic activity against lymphoid leukemia L1210 in mice.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6256765      PMCID: PMC350391          DOI: 10.1073/pnas.77.11.6865

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells.

Authors:  H E Skipper; F M Schabel; W S Wilcox
Journal:  Cancer Chemother Rep       Date:  1967-06

2.  Synthesis and anti-deoxyribonucleic acid virus activity of certain 9-beta-D-arabinofuranosyl-2-substituted adenine derivatives.

Authors:  K Miyai; L B Allen; J H Huffman; R W Sidwell; R L Tolman
Journal:  J Med Chem       Date:  1974-02       Impact factor: 7.446

3.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

4.  Deoxycytidine kinase. I. Distribution in normal and neoplastic tissues and interrelationships of deoxycytidine and 1-beta-D-arabinofuranosylcytosine phosphorylation.

Authors:  J P Durham; D H Ives
Journal:  Mol Pharmacol       Date:  1969-07       Impact factor: 4.436

5.  N6-(delta 2-isopentenyl)adenosine: its conversion to inosine, catalyzed by adenosine aminohydrolases from chicken bone marrow and calf intestinal mucosa.

Authors:  R H Hall; S N Alam; B D McLennan
Journal:  Can J Biochem       Date:  1971-06

6.  Nucleosides of 2-fluoroadenine.

Authors:  J A Montgomery; K Hewson
Journal:  J Med Chem       Date:  1969-05       Impact factor: 7.446

7.  Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy- -and- -D-erythro-pentofuranosyl)purines.

Authors:  L F Christensen; A D Broom; M J Robins; A Bloch
Journal:  J Med Chem       Date:  1972-07       Impact factor: 7.446

8.  Specificity of adenosine deaminase toward adenosine and 2'-deoxyadenosine analogues.

Authors:  S Frederiksen
Journal:  Arch Biochem Biophys       Date:  1966-02       Impact factor: 4.013

9.  Regulation of mammalian deoxyribonucleotide biosynthesis by nucleotides as activators and inhibitors.

Authors:  E C Moore; R B Hurlbert
Journal:  J Biol Chem       Date:  1966-10-25       Impact factor: 5.157

10.  Adenine and adenosine are toxic to human lymphoblast mutants defective in purine salvage enzymes.

Authors:  M S Hershfield; F F Snyder; J E Seegmiller
Journal:  Science       Date:  1977-09-23       Impact factor: 47.728

View more
  33 in total

1.  Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1.

Authors:  C Terai; R S Kornbluth; C D Pauza; D D Richman; D A Carson
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

2.  Effects of 2-chloroadenine substitution in DNA on restriction endonuclease cleavage reactions.

Authors:  P Hentosh; J C McCastlain
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

3.  Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.

Authors:  S Seto; C J Carrera; M Kubota; D B Wasson; D A Carson
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

Review 4.  Cellular and clinical pharmacology of fludarabine.

Authors:  Varsha Gandhi; William Plunkett
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.

Authors:  Tieran Han; Marilyn Fernandez; Ting-Chao Chou; Ram P Agarwal
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

6.  Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines.

Authors:  E H Chen; E E Johnson; S M Vetter; B S Mitchell
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.

Authors:  Kensei Tobinai; Naokuni Uike; Yoshio Saburi; Takaaki Chou; Tetsuya Etoh; Masato Masuda; Fumio Kawano; Masao Matsuoka; Hirokuni Taguchi; Torahiko Makino; Yoshinobu Asano; Kazuo Tamura; Yasuo Ohashi
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

8.  The treatment of chronic progressive multiple sclerosis with cladribine.

Authors:  E Beutler; J C Sipe; J S Romine; J A Koziol; R McMillan; J Zyroff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

9.  Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.

Authors:  D A Carson; D B Wasson; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

Review 10.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.